200 results on '"Frega Giorgio"'
Search Results
2. Histological and imaging features of myoepithelial carcinoma of the bone and soft tissue
3. Can repeated surgical resection offer a chance of cure for recurrent cholangiocarcinoma?
4. Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study
5. Myoepithelial carcinoma of soft tissues and bone
6. Tumor Immune Microenvironment in Intrahepatic Cholangiocarcinoma: Regulatory Mechanisms, Functions, and Therapeutic Implications.
7. The emerging role of intra-tumoral bacteria
8. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
9. NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report
10. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
11. The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma
12. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
13. An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone
14. Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
15. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
16. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
17. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center
18. Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study
19. Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
20. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
21. Risk-adjusted analysis of survival variability among hospitals treating biliary malignancy
22. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study
23. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
24. The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?
25. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
26. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis
27. Hacking Pancreatic Cancer: Present and Future of Personalized Medicine
28. Second-line FOLFOX chemotherapy for advanced biliary tract cancer
29. Caloric Restriction Mimetics, Autophagy, and Anticancer Immunosurveillance. ���The bacterial metabolite prodigiosin inhibits autophagy and suppresses antitumor immunity. Results from a fluorescent biosensor-based screening of bacterial metabolites���
30. Caloric Restriction Mimetics, Autophagy, and Anticancer Immunosurveillance. “The bacterial metabolite prodigiosin inhibits autophagy and suppresses antitumor immunity. Results from a fluorescent biosensor-based screening of bacterial metabolites”
31. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue
32. Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.
33. Second-line chemotherapy (2L) in elderly patients with advanced biliary tract cancer (ABC): A multicenter real-world study.
34. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.
35. Nivolumab: an investigational agent for the treatment of biliary tract cancer
36. Experimental HER2- targeted therapies for biliary tract cancer
37. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
38. Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements
39. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
40. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience
41. Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis
42. The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma
43. Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
44. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
45. How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis
46. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
47. TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS
48. BAP1 in solid tumors
49. Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments
50. Adjuvant treatment in biliary tract cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.